Nanotech Commercialization Conference, April 4-5, 2012, Research Triangle, Durham, North Carolina .
The Nanotech Commercialization Conference is the preeminent nanotechnology conference. Nanotech innovators, cutting edge start-ups, leading researchers, and visionary will be in attendance. If you are involved in the field, you should not miss this conference.
The NanoBusiness Commercialization Association recently recognized Nanotech
nology Evangelist Kelly Carnes, President and CEO of TechVision21 as one of the most influential nanotechnology leaders of 2011. Kelly will moderate a panel discussion at the Nanotech Commercialization Conference this week.
“Kelly’s major contributions to the leaders in the Nanotechnology Community is her deep understanding of the U.S. Government, her critical thinking and policy analysis”, said Vincent Caprio, Executive Director.
Over the last decade, the nanotechnology field has turned the corner from science fiction to multi-billion dollar business, rapidly becoming the center of the materials science field, and has made major game-changing innovations in clean energy, electronics and biotechnology.
The NanoBusiness Commercialization Association has joined the N.C. Department of Commerce and the Center of Innovation for Nanobiotechnology to co-host the Nanotechnology Commercialization Conference, a groundbreaking event for international nanotechnology stakeholders. “We are very pleased to be teaming with COIN on this exciting event,” noted Vincent Caprio, Executive Director of the NanoBCA. He added, “North Carolina is a hotbed for nanotechnology, particularly in the biotechnology sector. There are over 40 NanoBio companies located in North Carolina with leading research undertaken at Duke, UNC, NC State, Wake Forest and the region’s other universities.”
On Thursday, Kelly will moderate what promises to be a lively discussion on Trends in University Nanotechnology Research at the Nanotech Commercialization Conference.
Panelists include:
Suzy V. Torti, Ph.D., Professor of Biochemistry, Director, Biochemistry & Molecular Biology Graduate Program, Wake Forest University School of Medicine
Michael Dickey, Assistant Professor, Department of Chemical & Biomolecular Engineering, North Carolina State University and
William C. Zamboni PharmD, PhD, Associate Professor, DPET; Associate Member, Lineberger Comprehensive Cancer Center; Director, GLP Analytical Facility, UNC Eshelman School of Pharmacy, and UNC Lineberger Comprehensive Cancer Center
Dr. Torti’s laboratory is interested in iron metabolism, proteins of iron metabolism, and relationships between iron metabolism and cancer and nanotubes in thermal therapy/cancer/breast cancer/iron metabolism. Her lab is interested in relationships between iron metabolism and tumor growth.
Michael Dickey’s research interests are in developing alternative micro- and nano-fabrication techniques and studying the fundamental properties of the materials that are used or produced by these processes.
Photolithography—a “top down” approach to nanofabrication—is the state of the art in forming nanostructures, but it has several limitations (it is expensive, limited to planar surfaces, has limited resolution, etc). “Bottom up” techniques (e.g., the formation of nanowires in solution) are capable of forming small structures, but these techniques are generally incapable of creating the long-range order necessary to form useful devices.
Dickey is interested in alternative techniques that address one or more of these limitations (such as, imprint lithography, soft lithography, microfluidics, e-field assisted assembly, templated patterning, etc.) He is also experienced with photo-curable polymeric materials, particularly those used in both photo- and imprint lithography.
William Zamboni has been involved in translational studies of anticancer agents for several years.
A second focus of his research is on the developments of nanosomal and nanoparticle anticancer agents and evaluating the relationship between the disposition of these agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and is evaluating potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents and generate administration schedules to enhance selective tumor uptake.
Conference attendees will leave energized and inspired by game changing innovations and cutting edge research presented at this two day ground breaking event.